Key Takeaways Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its ...

Sarepta Therapeutics Inc. plummeted after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.

A second case of acute liver failure resulting in death has been reported in nonambulatory DMD patients treated with Elevidys.